Collegium PharmaceuticalCOLL
About: Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
Employees: 197
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
240% more call options, than puts
Call options by funds: $2.04M | Put options by funds: $599K
27% more repeat investments, than reductions
Existing positions increased: 94 | Existing positions reduced: 74
3% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 35
0% more funds holding
Funds holding: 227 [Q1] → 228 (+1) [Q2]
6.11% less ownership
Funds ownership: 127.24% [Q1] → 121.14% (-6.11%) [Q2]
19% less capital invested
Capital invested by funds: $1.58B [Q1] → $1.28B (-$302M) [Q2]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
Piper Sandler David Amsellem 66% 1-year accuracy 25 / 38 met price target | 4%downside $37 | Neutral Reiterated | 11 Oct 2024 |
HC Wainwright & Co. Oren Livnat 56% 1-year accuracy 22 / 39 met price target | 30%upside $50 | Buy Maintained | 5 Sept 2024 |
Piper Sandler David Amsellem 66% 1-year accuracy 25 / 38 met price target | 4%downside $37 | Neutral Reiterated | 9 Aug 2024 |
Truist Securities Les Sulewski 60% 1-year accuracy 3 / 5 met price target | 9%upside $42 | Buy Maintained | 9 Aug 2024 |
HC Wainwright & Co. Oren Livnat 56% 1-year accuracy 22 / 39 met price target | 22%upside $47 | Buy Upgraded | 30 Jul 2024 |
Financial journalist opinion
Based on 3 articles about COLL published over the past 30 days